Compliance with cardiovascular drug prevention measures in a general population: The Multidisciplinary Intervention in Primary Care (IMAP) study

European Journal of Preventive Cardiology

Volumn 19, Issue 5, 2012, Pages 1074-1081

  Lopez Carmona, D ^a   Bernal Lopez, M R ^b,c   Mancera Romero, J ^d   Jansen Chaparro, S ^a   Portales Fernandez, I ^a   Baca Osorio, A J ^d   Perez Gonzalez, R ^e   Tinahones, F J ^b,c   Gomez Huelgas, R ^a,c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Ciudad Jardín Health Center   (Spain)

^e Hospital University Carlos Haya de Málaga   (Spain)

Author keywords

Cardiovascular; drug therapy; primary prevention; secondary prevention

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY FAILURE; COMORBIDITY; CROSS-SECTIONAL STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POPULATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RANDOM SAMPLE; SECONDARY PREVENTION; ADOLESCENT; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEALTH SURVEY; METHODOLOGY; MIDDLE AGED; MORBIDITY; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MORBIDITY; POPULATION SURVEILLANCE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK FACTORS; SPAIN; YOUNG ADULT;

EID: 84873252808     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711418166     Document Type: Article

References (34)

1. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart J. 2006 ; 27 (13). 1610-1619
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
3. Yusuf S, Sleight P, Poghe J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342 (18). 145-153
4. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15). 1547-1559
5. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373 (9678). 1849-1860
6. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Betablokade after myocardial infarction: systematic review and meta regression analysis. BMJ.. 1999 ; 318 (7200). 1730-1737
7. Brophy JM, Joseph L, Rouleau JL. Beta-blokers in congestive Heart Failure. A Bayesian meta-analysis. Ann Intern Med. 2001 ; 134 (7). 550-560
8. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002 ; 360 (9326). 2-3
9. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006 ; 368 (9536). 679-686
10. Clinical reality of coronary prevention programmes: a comparison of EUROASPIRE I & II in 9 countries. Lancet. 2001 ; 357: 995-1001
11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 ; 373: 929-940
12. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 121-137
13. Boix R, Aragonés N, Medrano MJ. Trends in mortality from ischemic heart disease in 50 Spanish provinces. Rev Esp Cardiol. 2003 ; 56 (9). 850-856
14. Gomez-Huelgas R, Bernal-Lopez MR, Villalobos A, Mancera-Romero J, Baca-Osorio AJ, Jansen S, et al. Hypertriglyceridemic waist: an alternative to the metabolic syndrome? Results of the IMAP Study (Multidisciplinary Intervention in Primary Care). Int J Obes (Lond). 2011 ; 35 (2). 292-299
15. Gomez-Huelgas R, Mancera-Romero J, Bernal-Lopez MR, Jansen-Chaparro S, Baca-Osorio AJ, Toledo E, et al. Prevalence of cardiovascular risk factors in an urban adult population from southern Spain. IMAP Study. Int J Clin Pract. 2011 ; 65 (1). 35-40
16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 ; 130 (6). 461-470
18. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice: fourth joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 28 (19). 2375-2414
19. Lobos JM, Royo-Bordonada MA, Brotons C, Álvarez-Sala L, Armario P, Maiques A. Comité Español Interdisciplinario para la Prevención Cardiovascular. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation. Rev Clin Esp. 2009 ; 209 (6). 279-302
20. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project 1. Eur Heart J. 2003 ; 24 (11). 987-1003
21. Standards of medical care in diabetes - 2009. Diabetes Care. 2010 ; 33 (Suppl. 1). S11 - S61
22. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens. 2003 ; 21 (6). 1011-1053
23. National Collaborating Centre for Chronic Conditions. Hypertension: Management of hypertension in adults in primary care: Partial update. London, UK: Royal College of Physicians ; 2006.
24. Charlson ME, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987 ; 40 (5). 373-383
25. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Z, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (5). 530-540
26. Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, Bayer NH, et al. Vascular Protection; Guidelines-Oriented Approach to Lipid-Lowering Registries Investigators; Stroke Outcome Research Canada Working Group Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?. Stroke. 2009 ; 40 (4). 1417-1424
27. Flu HC, Tamsma JT, Lindeman JH, Hamming JF, Lardenoye JH. A systematic review of implementation of established recommended secondary prevention measures in patients with PAOD. Eur J Vasc Endovasc Surg. 2010 ; 39 (1). 70-86
28. Zeymer U, Parhofer KG, Pittrow D, Binz C, Schwertfeger M, Limbourg T, et al. Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol. 2009 ; 98 (4). 249-256
29. Tjia J, Briesacher B, Xie D, Fu J, Goldberg RJ. Disparities in combination drug therapy use in older adults with coronary heart disease: a cross-sectional time-series in a nationally representative US sample. Drugs Aging. 2010 ; 27 (2). 149-158
30. Michou SM, Kähönen M, Lehtimäki T, Nikus K, Viik J, Niemelä K, et al. Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting. Clin Drug Investig. 2007 ; 27 (10). 673-681
31. Tuppin P, Neumann A, Danchin N, Weill A, Ricordeau P, de Peretti C, et al. Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. Arch Cardiovasc Dis. 2009 ; 102 (4). 279-292
32. Keller H, Krones T, Becker A, Hirsch O, Sönnichsen AC, Popert U, et al. Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. Eur J Cardiovasc Prev Rehabil 2011 Mar 24. [Epub ahead of print].
33. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of «statin» lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001 ; 161 (1). 53-58
34. Brotons C. Evaluating the model SCORE for calculating cardiovascular risk in primary health care. Rev Esp Salud Publica. 2005 ; 79 (4). 439-442